SCHEMBL324667

SCHEMBL324667

COc1ccc(COC(=O)N2C=Cc3ccccc3C2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 3/20 0.48
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
GRIN2B Q13224 1/20 0.41
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ATM Q13315 1/20 0.40
FABP7 O15540 1/20 0.40
FABP5 Q01469 1/20 0.40
ALDH1A1 P00352 3/20 0.40
ADORA3 P0DMS8 1/20 0.39
MMP1 P03956 1/20 0.39
MMP9 P14780 1/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324346 0.89 P2RX4 (0.47) P2RX4GRIN2BRAB9ASMN1; SMN2ALDH1A1
SCHEMBL324299 0.87 P2RX4 (0.52) P2RX4RAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL323321 0.87 NPC1 (0.47) P2RX4RAB9AALDH1A1MMP1MMP9
SCHEMBL324380 0.85 P2RX4 (0.42) P2RX4GRIN2BRAB9AFABP7FABP5
SCHEMBL324120 0.85 P2RX4 (0.46) P2RX4RAB9AALDH1A1MMP1MMP9
SCHEMBL324830 0.84 LIPE (0.44) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL325470 0.83 KDM4E (0.44) SMN1; SMN2ALDH1A1MAPTTAS1R3TAS1R1
SCHEMBL22411030 0.83 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL324069 0.82 MMP12 (0.40) P2RX4RAB9AMMP1NPC1
SCHEMBL325479 0.81 RECQL (0.41) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 P2RX4 88/4885CHRM5 363/4885CHRM1 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.